Market Access
How new PBM transparency rules will alter drug pricing
The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.
News
AZ's gMG drug Klygefa nears EU approval
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
Market Access
Sponsored
From first approval to lasting value: What sets successful e...
Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
News
Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Market Access
Request to look further into NICE non-submissions in the fut...
Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
